‘Grandma and grandpa aren’t going to figure this one out.’ Prescription-drug savings vanish in the Medicare shuffle

For Medicare patients struggling to afford the Biogen
BIIB,
+0.08%
multiple sclerosis drug Tecfidera, the arrival last year of far cheaper generic competitors should have been great news. Instead, it has become a cautionary tale about the Medicare prescription-drug benefit’s complexities proving costly to patients and taxpayers, drug-pricing researchers say.

Read the source article at News Break
2021-12-10 18:13:00